Vertex Pharmaceuticals (VRTX) and Crispr Therapeutics (CRSP) announced that they have entered into a new non-exclusive licensing agreement for the use of Crispr Therapeutics’ gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex’s hypoimmune cell therapies for type 1 diabetes, or T1D. Under this agreement, Vertex will pay Crispr Therapeutics $100M up-front for non-exclusive rights to Crispr Therapeutics’ technology for the development of hypoimmune gene-edited cell therapies for T1D. Crispr Therapeutics will be eligible for up to an additional $230M in research and development milestones and receive royalties on any future products resulting from this agreement.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
- VRTX, BIIB, or IQV: Which Biotech Stock Could Deliver the Highest Return?
- Vertex Pharmaceuticals initiated with an Outperform at Bernstein
- Vertex says FDA clears IND for VX-264 with potential to treat type 1 diabetes
- Immunogen confident in early Elahere launch, says Guggenheim
- ImmunoGen announces license agreement with Vertex Pharmaceuticals
